Physician profile
Brett B Ernst
NPI 1346261765
$5,940.30
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $726 · 2020: $802 · 2021: $2,498 · 2022: $1,592 · 2023: $306 · 2024: $15.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $322.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,186.35 | 2019-2022 | |
| Notal Vision, INC. | $1,029.62 | 2022 | |
| Ivantis, INC | $563.21 | 2020-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $525.36 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $251.97 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $178.51 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $170.81 | 2019-2023 | Cequa |
| Mallinckrodt Hospital Products INC. | $165.99 | 2021-2022 | |
| Aerie Pharmaceuticals, INC. | $130.98 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $112.90 | 2022-2024 | Victus, Miebo |
| Alcon Vision LLC | $98.75 | 2023 | Rocklatan, Hydrus Microstent |
| Oyster Point Pharma, INC. | $92.91 | 2022-2023 | Tyrvaya |
| Horizon Therapeutics Plc | $61.93 | 2022 | |
| Abbvie INC. | $50.89 | 2022-2023 | |
| Biotissue Holdings INC. | $46.56 | 2021-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $38.94 | 2022-2023 | Acuvue |
| Kala Pharmaceuticals, INC. | $37.74 | 2021-2022 | |
| Glaukos Corporation | $32.23 | 2022 | |
| Akorn Operating Company LLC | $30.28 | 2021 | |
| Rayner Intraocular Lenses Limited | $29.99 | 2023 | Omidria, Rayone Emv, Rayone Aspheric |
| New World Medical,INC. | $27.31 | 2019 | |
| Rxsight INC | $23.79 | 2022 | |
| Eyepoint US, INC. | $22.30 | 2020 | |
| Sight Sciences, INC. | $16.56 | 2022 | |
| Shire North American Group INC | $14.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Ernst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.